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Abstract
Background: Propofol is a rapid, efﬁcient hypnotic agent with antiemetic effects. However, a high dosage is related to
hemodynamic abnormalities such as hypotension and bradycardia. Pretreatment with remifentanil can decrease injection pain and
stabilize hemodynamics during the induction period. Remifentanil or midazolam in combination with propofol can provide synergistic
or additive effects during anesthesia induction. However, the hypnotic doses of propofol required in patients who receive
pretreatment with remifentanil or midazolam remain unclear.
Methods: Patients aged 20 to 50 years who were scheduled to undergo surgery under general anesthesia were enrolled in this
study. The patients were randomized into 3 groups using a computer-generated randomization table. Patients in Group P (Propofol)
received only propofol for loss of consciousness, those in Group PR (Propofol-Remifentanil) received remifentanil prior to propofol,
and those in Group PMR (Propofol-Midazolam-Remifentanil) received remifentanil and midazolam prior to propofol. After propofol
administration, loss of both the eyelash reﬂex and verbal response represented success. The 95% effective dose of propofol for loss
of consciousness in each group, which was the primary outcome, was determined using a modiﬁed biased coin up-and-down
method.
Results:A total of 124 patients were initially enrolled. Of these, 4 were excluded, and the remaining 120 patients were randomized
to each (n=40) of the 3 groups. The 95% effective dose of propofol for loss of consciousness was 1.74 , 1.38, and 0.92mg/kg in
Groups P, PR, and PMR, respectively. Blood pressure decreased at 2minutes after propofol administration in all the groups.
However, compared with Group P, Groups PR and PMR exhibited a signiﬁcant decrease in blood pressure.
Conclusions: The effective dose of propofol for loss of consciousness could be decreased by 21% and 47% when remifentanil
pretreatment was used without and with midazolam, respectively. However, the decrease in blood pressure was greater with
pretreatment than sole propofol use. These ﬁndings suggest that the combination of remifentanil with or without midazolammay have
no beneﬁt on hemodynamic stability during induction using propofol.
Trial registration: NCT02536690 (clinicaltrials.gov).
Abbreviations: ANOVA = analysis of variance, ASA = American Society of Anesthesiologists, BMI = body mass index, CI =
conﬁdence interval, ED95 = 95% effective dose, HR = heart rate, MBP = mean blood pressure, SpO2 = oxygen saturation.
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Propofol is a rapidly acting, unpungent hypnotic agent with
antiemetic properties. Several anesthesiologists use this agent for
the induction of general anesthesia. However, a high dosage is
related to hypotension and/or bradycardia, with possible
underlying mechanisms including the negative inotropic or
peripheral vasodilation effects of propofol.[1,2] Therefore, the use
of propofol for the induction of anesthesia in patients with
susceptible comorbidities can lead to the occurrence of serious
and dangerous cardiovascular complications.
Previous studies reported that opioids or benzodiazepines used
in combination with propofol provided additive or synergistic
effects that could decrease the required dose of propofol for
several procedures.[3–6] Midazolam is a benzodiazepine com-
monly used as a pretreatment agent to decrease anxiety and
improve patient satisfaction levels.[7] Remifentanil is an opioid
used for intraoperative pain control. Pretreatment with remi-
fentanil can decrease injection pain[8] and provide hemodynamic
stability during the induction period.[9,10] However, the required
bolus dose of propofol for loss of consciousness during induction
in patients who receive pretreatment with remifentanil or
midazolam remains unclear. Furthermore, the effects of premed-
ication with remifentanil or midazolam on the patient’s
hemodynamics have not been elucidated.
Therefore, in this randomized controlled trial, we investigated
and compared the effects of no pretreatment, remifentanil
pretreatment, and remifentanil plus midazolam pretreatment on
the 95% effective dose (ED95) of propofol for loss of
consciousness during induction.2. Methods
This study was approved by the Institutional Review Board
(approval no: 2015-0183-004) of Gangnam Severance Hospital,
Seoul, Korea and registered at clinicaltrials.gov (NCT02536690).
A total of 124 patients (age, 20–50 years) scheduled for surgery
under general anesthesia were enrolled in this study. Patients with
an American Society of Anesthesiologists (ASA) physical status of
III or IV, those with a history of adverse effects caused by the
study drugs, and those with a body mass index of20 or≥30kg/
m2 were excluded.
After obtaining informed consent from all the patients, we
randomized them into 3 groups using a computer-generated
randomization table.
Before transfer to the operation room, an 18-gauge intrave-
nous catheter was inserted at the patient’s basilic vein and 5mL/
kg of 0.9% normal saline was infused before the induction.
Intravenous glycopyrrolate 0.2mg was administered as premed-
ication to all the patients. In the operating room, the patients were
monitored with electrocardiography, pulse oximetry, noninva-
sive blood pressure measurements, and multigas analysis.
Each patient received intravenous propofol after 5minutes of
preoxygenation. In Group P (Propofol), no additional drug
except propofol was used for the induction. In Groups PR
(Propofol-Remifentanil) and PMR (Propofol-Midazolam-Remi-
fentanil), remifentanil 0.25mg/kg/min was intravenously infused
from the start of preoxygenation until 2minutes after propofol
administration. In Group PMR, intravenous midazolam 0.05mg/
kg was additionally administered 1minute after preoxygenation.
After the predetermined dose of propofol was administered,
loss of the eyelash reﬂex and verbal response was assessed for
2minutes. Induction success was represented by loss of both the2eyelash reﬂex and verbal response. Other cases were considered
failures.
The dose of propofol used for each patient was determined
according to the success or failure of induction in the previous
patient using a modiﬁed biased coin up-and-down method.[11,12]
The initial dose was set as 1.0mg/kg for each group; this was the
least successful hypnotic dose of propofol in a previous study.[4] If
induction failed in 1 patient, the dose for the next patient was
increased by 0.25mg/kg. If induction was successful in 1 patient,
the dose for the next patient was determined by a randomly
selected card from a total of 19 cards. With a probability of 1/19,
the dose for the next patient was decreased by 0.25mg/kg, and
the same dose was administered with a probability of 18/19.
The mean blood pressure (MBP), heart rate (HR), and oxygen
saturation (SpO2) of all the patients were recorded at baseline,
before propofol administration, and 1 and 2minutes after
propofol administration. Any adverse effects were monitored and
recorded.2.1. Statistical analysis
Aminimum of 40 subjects were required according to simulation
based on themethods byDurham et al.[11] Therefore, we included
40 patients in each group in the present study.
All the statistical analyses were performed using the R for
Windows (version 3.2.0; The R Foundation for Statistical
Computing; https://www.r-project.org) for isotonic regression
and SAS (version 9.2; SAS Institute, Cary, NC) for linear mixed-
model analyses and analysis of variance (ANOVA). To derive
regression models allowing the prediction of the effective dose of
propofol for the successful loss of consciousness in 95% patients
(ED95), isotonic regression using the pooled adjacent violators
algorithm (PAVA) was performed for each group. A boot-
strapping approach to produce 95% conﬁdence intervals (CIs)
was used for the estimates of ED95. ANOVA and a linear mixed
model were used to analyze the demographic characteristics and
hemodynamic changes for each group. A P value of< .05 was
considered statistically signiﬁcant.3. Results
From the total of 124 patients, 4 refused to participate in the
study. The remaining 120 patients were equally randomized (n=
40 each) into the 3 groups.
The demographic characteristics of the enrolled patients are
shown in Table 1. There were no signiﬁcant differences in any
characteristic among the 3 groups. The allocation sequence for
each group according to the biased coin design is demonstrated in
Fig. 1. The PAVA response rate for each group is shown in Fig. 2.
For the higher success rate for loss of consciousness, Group P
required higher dose of propofol, followed by Group PR and
Group PMR. The ED95 of propofol was 1.74, 1.38, and 0.92mg/
kg in Groups P, PR, and PMR, respectively (Table 2). MBP and
HR measured at each time point are shown in Fig. 3. In all the
groups, MBP was decreased at both 1 and 2minutes after
propofol administration compared with baseline (P< .001 for all
the groups at each time). However, in Group PMR, MBP was
also decreased before propofol administration (P< .001).
Though there were no intergroup differences at other time
points, MBP was more signiﬁcantly decreased at Groups PR and
PMR compared with Group P at 2minutes after propofol
administration (P< .02 and P< .01, respectively).
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Figure 2. The pooled adjacent violators algorithm response rate for each
group. For the higher success rate for loss of consciousness, Group P required
higher dose of propofol, followed by Group PR and Group PMR. Group P:
patients who received only propofol for loss of consciousness. Group PR:
patients who received remifentanil (0.25mg/kg/min) prior to propofol. Group
PMR: patients who received both midazolam (0.05mg/kg) and remifentanil
Table 1
Demographic characteristics of patients in each group.
Group P (n=40) PR (n=40) PMR (n=40) P value
Age 37.9±8.7 35.7±7.9 38.3±8.9 .83
Height, cm 160.8±5.7 161.1±5.0 161.0±4.9 .91
Weight, kg 57.5±7.4 56.6±6.5 57.4±7.7 .91
BMI, kg/m2 22.3±3.0 21.8±2.6 22.2±3.1 .86
Values are expressed as means± standard deviations.
Group P: patients who received only propofol for loss of consciousness. Group PR: patients who
received remifentanil (0.25mg/kg/min) prior to propofol. Group PMR: patients who received both
midazolam (0.05mg/kg) and remifentanil prior to propofol.
BMI=body mass index.
Koh et al. Medicine (2017) 96:49 www.md-journal.comCompared with the baseline value, HR exhibited a signiﬁcant
decrease at 0, 1, and 2minutes after propofol administration only
in Group PMR (P< .001). In Group PR, the HR decreased at 2
minutes after propofol administration compared with baseline.
However, HR exhibited a signiﬁcant decrease at 1minute (P= .05
compared with that before propofol administration), followed by0.00
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Figure 1. Assessment of success or failure of anesthesia induction by a
predetermined bolus dose of propofol determined for consecutive patients
using a modiﬁed biased coin design in each group. Induction success (loss of
consciousness) is indicated by solid circles, and induction failure (no loss of
consciousness) is indicated by open circles. Group P: patients who received
only propofol for loss of consciousness. Group PR: patients who received
remifentanil (0.25mg/kg/min) prior to propofol. Group PMR: patients who
received both midazolam (0.05mg/kg) and remifentanil prior to propofol.
prior to propofol.
3a further signiﬁcant decrease at 2minutes (P< .001 compared
with that at 1minute) in Group PR. There were no intergroup
differences in HR at each time point. No adverse effects related to
the administered drugs were recorded.4. Discussion
In this randomized controlled trial, we investigated and
compared the effects of no pretreatment (Group P), remifentanil
pretreatment (Group PR), and remifentanil plus midazolam
pretreatment (Group PMR) on the ED95 of propofol on patients
aged 20 to 50 years old for loss of consciousness during
induction. The results indicated that the required hypnotic dose
of propofol was lower when the patients received pretreatment
with remifentanil or both remifentanil or midazolam. However,
MBP and HR decreased more with pretreatment than without
pretreatment.
Some studies have reported the propofol dose-sparing effects of
remifentanil and midazolam. The ﬁndings of our study were
consistent with the ﬁndings of these previous studies.[3,4,6]
Pretreatment with remifentanil during induction has some
advantages. The optimal dosage of remifentanil pretreatment
can offer hemodynamic stability during maneuvers in the
induction period, including laryngoscopy and intubation,[9,10]
and it was also shown to have protective effects on organs in
animal studies.[13–15] In addition, it is reported that remifentanilTable 2
The 95% effective dose of propofol required for loss of
consciousness in each group.
Group ED95 (mg/kg) 95% CI
P 1.74 1.61–2.34
PR 1.38 1.23–1.61
PMR 0.92 0.79–1.13
Group P: patients who received only propofol for loss of consciousness. Group PR: patients who
received remifentanil (0.25mg/kg/min) prior to propofol. Group PMR: patients who received both
midazolam (0.05mg/kg) and remifentanil prior to propofol.
CI=conﬁdence interval, ED95=95% effective dose.
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Figure 3. Mean blood pressure and heart rate values at baseline, before
propofol administration, and 1 and 2minutes after propofol administration in
each group. Values are presented as mean±standard deviation. MBP was
more signiﬁcantly decreased at Group PR and PMR compared with Group P at
2minutes after propofol administration (P= .02 and P= .01, respectively). There
were no intergroup differences in HR at each time point.
∗
, †, ‡: Signiﬁcantly
decreased compared with baseline values in Group P, Group PR, and Group
PMR, respectively (P< .05). x: Signiﬁcantly decreased compared with Group P.
MBP=mean blood pressure, HR=heart rate, 0min, 1min, 2min=before and
1 and 2minutes after propofol administration, respectively. Group P: patients
who received only propofol for loss of consciousness. Group PR: patients who
received remifentanil (0.25g/kg/min) prior to propofol. Group PMR: patients
who received both midazolam (0.05g/kg) and remifentanil prior to propofol.
Koh et al. Medicine (2017) 96:49 Medicinepretreatment can prevent pain caused by propofol injection. A
few studies used target-controlled infusion to investigate the
hypnotic dose of propofol when combined with remifentanil and
the effects of combined treatment on hemodynamics.[3,6] Target-
controlled infusion requires special equipment that needs time to
be set up. In addition, this technique may not be accurate in
situations where several drugs are used in combination,
particularly in the induction period.[16] In clinical practice,
several clinicians administer the study drugs according to the
patient’s weight. Therefore, we designed this study using weight-
based calculations for the drug dose.
Previous studies have suggested that propofol should be
administered at lower doses in the elderly or when used in
combination with other agents.[4–6,17] Nevertheless, several
clinicians still use an induction dose of up to 2.5mg/kg (ED95
of propofol), even when midazolam or remifentanil are
administered for premedication and analgesia during the
induction period.[17] A possible reason could be the lack of
clinical data on the ED95 of propofol when used in combination
with midazolam or remifentanil. The ﬁndings of our study
suggest that the ED95 of propofol can be decreased in patients
who receive pretreatment.4Although we were able to lower the propofol dose for loss of
consciousness by remifentanil pretreatment with or without
midazolam, the decrease in MBP and HR was greater with
pretreatment thanwithout pretreatment.Remifentanil is often used
to induce hypotension during surgery.[18,19] The decrease in blood
pressure is thought to be due to a decrease in the regional vascular
tone.[20] However, remifentanil is known for better maintenance of
hemodynamic stability and the cerebral blood ﬂow compared with
other currently used opioids,[21] although the decrease in blood
pressure becomes more conspicuous when it is administered in
combinationwith propofol.[22] In the present study, blood pressure
did not decrease until propofol was administered in Groups P and
PR,whereas it began to decrease before propofolwas administered
in Group PMR. Midazolam does not usually decrease blood
pressurewhen used alone.[23]The decrease inMBPobservedbefore
propofol administration inGroup PMR in the present study can be
attributed to a decrease in anxiety induced by midazolam.[7]
However, because the initial MBP of the study subjects was in the
normal range of 88.2mmHg, there is a possibility that midazolam
synergized with remifentanil to cause the decrease in blood
pressure.[24] Further studies would provide a more clear under-
standing of the interaction between the 2 drugs.
Bradycardia is commonly caused by remifentanil,[22,25] proba-
bly because of vagal or chronotropic effects. However, the exact
mechanism remains unclear.[25,26] In the present study,HRdid not
decrease until propofol was administered in Groups P and PR,
although it decreased after the administration of propofol. In
Group PR in particular, HR decreased more sharply compared
with that inGroupP, suggesting that the chronotropic effects of the
2 drugs are synergistic. In contrast, in Group PMR, HR decreased
from the early stages, before propofol administration. However,
there was no signiﬁcant difference in HR between Groups PMR
and PR at 2minutes after propofol administration. This was
probably caused by blunting of theHRdecrease due to incomplete
anxiolysis in the early induction period in Group PR.[7]
This study has several limitations. First, because endotracheal
intubation requires a much higher dose of anesthetic compared
with the dose required for loss of consciousness, we used an
inhalation agent and muscle relaxants after loss of consciousness
to obtain deeper analgesia and muscle relaxation for intubation.
Therefore, the response to stimuli such as tracheal intubation and
hemodynamic changes during surgery could not be investigated.
Second, relatively healthy adult patients were enrolled in our
study. Because patients may have different sensitivity to the drugs
by their age, the result of this study may not be well applicable to
the elderly. Considering that the hemodynamic changes can be
more devastating in elderly patients, further research on elderly
patients seems necessary.5. Conclusions
The effective dose of propofol for loss of consciousness could be
decreased by 21% and 47%when remifentanil pretreatment was
used without and with midazolam, respectively. However, the
decrease in blood pressure was greater with pretreatment than
sole propofol use. These ﬁndings suggest that the combination of
remifentanil with or without midazolam may have no beneﬁt on
hemodynamic stability during induction using propofol.Acknowledgment
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